Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Paul G. Baverel"'
Autor:
Van Thuy Truong, Paul G. Baverel, Grant D. Lythe, Paolo Vicini, James W. T. Yates, Vincent F. S. Dubois
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 11, Iss 2, Pp 133-148 (2022)
Abstract Mathematical models in oncology aid in the design of drugs and understanding of their mechanisms of action by simulation of drug biodistribution, drug effects, and interaction between tumor and healthy cells. The traditional approach in phar
Externí odkaz:
https://doaj.org/article/dc79b06dc75c496da221860c1d493470
Autor:
Ignacio González‐García, Vadryn Pierre, Vincent F. S. Dubois, Nassim Morsli, Stuart Spencer, Paul G. Baverel, Helen Moore
Publikováno v:
CPT: Pharmacometrics & Systems Pharmacology, Vol 10, Iss 3, Pp 230-240 (2021)
Abstract We developed and evaluated a method for making early predictions of best overall response (BOR) and overall survival at 6 months (OS6) in patients with cancer treated with immunotherapy. This method combines machine learning with modeling of
Externí odkaz:
https://doaj.org/article/8fbcb3e56e864a4ab7bd5c18996aa967
Publikováno v:
Contemporary Clinical Trials Communications, Vol 26, Iss , Pp 100901- (2022)
Background: Escalation With Overdose Control (EWOC) designs are increasingly used to ensure dose-toxicity curve of investigational oncology drugs is efficiently characterized during dose escalation steps. We propose a novel EWOC-based method that int
Externí odkaz:
https://doaj.org/article/a52fc09ad4fd4cc3980f2b87feecd43c
Autor:
Rosalinda Arends, Xiang Guo, Paul G. Baverel, Ignacio González-García, James Xie, Nassim Morsli, Alejandro Yovine, Lorin K. Roskos
Publikováno v:
OncoImmunology, Vol 10, Iss 1 (2021)
The potential for durvalumab, a programmed cell death ligand-1 (PD-L1)-blocking monoclonal antibody, to treat head and neck squamous cell carcinoma (HNSCC) is being evaluated in multiple clinical trials. We assessed circulating proteins at baseline t
Externí odkaz:
https://doaj.org/article/d1da9b630d8e4d918460f1a380d61eb4
Autor:
John Hood, Ignacio González-García, Nicholas White, Leeron Marshall, Vincent F. S. Dubois, Paolo Vicini, Paul G. Baverel
Publikováno v:
Pharmaceutics, Vol 13, Iss 4, p 519 (2021)
A sequential pharmacokinetic (PK) and pharmacodynamic (PD) model was built with Nonlinear Mixed Effects Modelling based on data from a first-in-human trial of a novel biologic, MEDI7836. MEDI7836 is a human immunoglobulin G1 lambda (IgG1λ-YTE) monoc
Externí odkaz:
https://doaj.org/article/15fd3f60ba624730ac3cd9d0a9f7dae2
Publikováno v:
Journal of Pharmacokinetics and Pharmacodynamics. 38:63-82
When parameter estimates are used in predictions or decisions, it is important to consider the magnitude of imprecision associated with the estimation. Such imprecision estimates are, however, presently lacking for nonparametric algorithms intended f
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bfa20acd151a88ecd281c5605ca94908
https://doi.org/10.1007/s10928-010-9177-x
https://doi.org/10.1007/s10928-010-9177-x
Autor:
Paul G, Baverel, Meena, Jain, Iwona, Stelmach, Dewei, She, Balaji, Agoram, Sara, Sandbach, Edward, Piper, Piotr, Kuna
Publikováno v:
British journal of clinical pharmacology. 80(6)
Tralokinumab, an investigational human immunoglobulin G4 monoclonal antibody, potently and specifically neutralizes interleukin-13, a central mediator of asthma. Tralokinumab has shown improvements in clinical endpoints in adults with uncontrolled as
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c76602648850dfd390a28a2ef3860792
https://pubmed.ncbi.nlm.nih.gov/26182954
https://pubmed.ncbi.nlm.nih.gov/26182954
Publikováno v:
Journal of pharmacokinetics and pharmacodynamics. 36(4)
The aim of the study was to evaluate the nonparametric estimation methods available in NONMEM VI in comparison with the parametric first-order method (FO) and the first-order conditional estimation method (FOCE) when applied to real datasets. Four me
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::426e38010414a7e3fcc25e427f9b6020
https://pubmed.ncbi.nlm.nih.gov/19572188
https://pubmed.ncbi.nlm.nih.gov/19572188
Publikováno v:
Journal of Allergy and Clinical Immunology. 132:847-855.e5
Inhaled capsaicin elicits cough reproducibly in human subjects and is widely used in the study of cough and antitussive therapies. However, the traditional end points C2 and C5 (the concentrations of capsaicin inducing at least 2 or 5 coughs, respect
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3063779ba8694801930cf23d2962d0b9
https://doi.org/10.1016/j.jaci.2013.04.042
https://doi.org/10.1016/j.jaci.2013.04.042